Phospho-RPS6KA5 (T581) Antibody

What is RPS6KA5 and why is phosphorylation at T581 significant?

RPS6KA5 (also known as MSK1) is a serine/threonine-protein kinase that functions as a critical downstream effector in the MEK/ERK signaling pathway. Located on chromosome 14 in humans, this 90kDa protein plays a fundamental role in regulating gene expression and cellular responses to various stimuli .

The T581 site represents a critical phosphorylation position that directly correlates with the activation state of the kinase. When phosphorylated at T581, RPS6KA5 undergoes a conformational change that substantially increases its catalytic activity, enabling it to phosphorylate downstream targets including transcription factors CREB1, ATF1, RELA, STAT3, and ETV1/ER81 . This phosphorylation is particularly important because it represents a convergence point for multiple upstream signaling pathways, including the MEK/ERK cascade and p38 MAPK pathways, making it an excellent biomarker for active signaling through these networks .

What are the technical specifications of commercially available Phospho-RPS6KA5 (T581) antibodies?

Available Phospho-RPS6KA5 (T581) antibodies are typically polyclonal antibodies raised in rabbits against synthetic peptides derived from human RPS6KA5 surrounding the T581 phosphorylation site. The following table summarizes the key specifications of these antibodies:

How does the phosphorylation state of RPS6KA5 at T581 affect its function?

Phosphorylation of RPS6KA5 at the T581 residue serves as a critical activation switch that determines the protein's functional capabilities. In its non-phosphorylated state, RPS6KA5 exhibits minimal kinase activity. Upon phosphorylation at T581, typically through the action of upstream kinases in the MEK/ERK pathway or MAPK14/p38-alpha, RPS6KA5 undergoes a conformational change that significantly enhances its catalytic activity .

When activated through T581 phosphorylation, RPS6KA5 can:

• Phosphorylate histone H3, leading to chromatin remodeling that facilitates the transcription of immediate early genes such as c-fos/FOS and c-jun/JUN

• Activate transcription factors including CREB1, ATF1, RELA, and STAT3 through phosphorylation

• Modulate inflammatory gene expression through interactions with glucocorticoid receptors and regulation of NF-κB activity

• Participate in neuronal cell death and growth factor signaling pathways

These diverse functions make phospho-RPS6KA5 (T581) detection crucial for understanding cellular signaling dynamics in both normal physiology and pathological conditions.

What are the optimal experimental conditions for detecting Phospho-RPS6KA5 (T581) in different applications?

The detection of phosphorylated RPS6KA5 at T581 requires careful optimization across different experimental platforms. Based on extensive research applications, the following methodological guidelines can maximize detection sensitivity and specificity:

Western Blotting (WB):

• Recommended dilution: 1:500-1:2000

• Sample preparation: Lyse cells in buffer containing phosphatase inhibitors (sodium orthovanadate, sodium fluoride, and β-glycerophosphate)

• Loading control: Total RPS6KA5 antibody on separate blots or after stripping

• Expected band size: 111 kDa (observed) vs 89.9 kDa (calculated)

Immunohistochemistry (IHC):

• Recommended dilution: 1:100-1:300

• Antigen retrieval: Citrate buffer (pH 6.0) heat-induced epitope retrieval

• Blocking: 3-5% BSA in PBS for 1 hour at room temperature

• Detection system: HRP-conjugated secondary antibody with DAB substrate

Immunofluorescence (IF):

• Recommended dilution: 1:200-1:1000

• Fixation: 4% paraformaldehyde for 15 minutes

• Permeabilization: 0.1-0.3% Triton X-100 for 10 minutes

• Blocking: 5% normal goat serum in PBS with 0.1% Tween-20

ELISA:

• Recommended dilution: 1:40000

• Coating concentration: 1-2 μg/ml of capture antibody

• Sample preparation: Serial dilutions to establish detection range

• Detection: HRP-conjugated secondary antibody with TMB substrate

How can I validate the specificity of Phospho-RPS6KA5 (T581) antibody signals in my experiments?

Validating antibody specificity is crucial for obtaining reliable data when working with phospho-specific antibodies. Multiple approaches should be employed to confirm the specificity of Phospho-RPS6KA5 (T581) antibody signals:

• Phosphatase Treatment Control:

  • Split your sample into two portions

  • Treat one portion with lambda phosphatase

  • The phospho-specific signal should disappear in the treated sample

• Stimulation/Inhibition Experiments:

  • Stimulate cells with PMA or EGF to activate the MEK/ERK pathway (increasing T581 phosphorylation)

  • Treat cells with MEK inhibitors (U0126, PD98059) or p38 inhibitors (SB203580) to reduce T581 phosphorylation

  • Compare signal intensities between conditions to confirm phospho-specificity

• Blocking Peptide Competition:

  • Pre-incubate the antibody with a synthesized phospho-T581 peptide

  • The specific signal should be significantly reduced or eliminated

• Genetic Controls:

  • Use RPS6KA5 knockout or knockdown models as negative controls

  • Use T581A mutant (non-phosphorylatable) as a negative control

  • Compare with wild-type samples to confirm specificity

• Comparison with Total RPS6KA5:

  • Always run parallel detection of total RPS6KA5 protein

  • Calculate the ratio of phosphorylated to total protein to normalize for expression differences

These validation steps ensure that the observed signals genuinely represent phosphorylated RPS6KA5 at T581 rather than nonspecific binding.

How can I differentiate between RPS6KA5 (MSK1) and related kinases when using phospho-specific antibodies?

The RPS6K family contains several structurally similar kinases, particularly RPS6KA4 (MSK2), which shares significant sequence homology with RPS6KA5. Careful experimental design and data interpretation are necessary to ensure specificity:

• Sequence alignment analysis: The region surrounding T581 in RPS6KA5 shares some homology with corresponding regions in related kinases. Before beginning experiments, perform sequence alignments to identify potential cross-reactivity.

• Molecular weight discrimination: RPS6KA5 has an observed molecular weight of 111 kDa , which differs from other family members:

  • RPS6KA4 (MSK2): ~90 kDa

  • RPS6KA1 (RSK1): ~90 kDa

  • RPS6KA3 (RSK2): ~90 kDa

• Isoform-specific knockdown: Use siRNA or shRNA specifically targeting RPS6KA5 to confirm signal identity. A genuine RPS6KA5 signal should decrease with specific knockdown but remain unaffected by knockdown of related family members.

• Phosphorylation-site verification: Consider complementary techniques such as mass spectrometry to definitively identify the phosphorylated residue in immunoprecipitated samples.

• Cell type specificity: Be aware that expression patterns of RPS6K family members vary across tissues and cell types, which can affect interpretation of results.

What are the expected phosphorylation dynamics of RPS6KA5 T581 in response to different stimuli?

The phosphorylation of RPS6KA5 at T581 follows distinct temporal patterns depending on the stimulus and cell type. Understanding these dynamics is crucial for proper experimental design and data interpretation:

When designing experiments:

• Include multiple time points to capture the full phosphorylation profile

• Consider the potential for biphasic responses in some cell types

• Always include appropriate positive controls (e.g., PMA stimulation for 30 minutes)

• Use pathway-specific inhibitors to confirm the signaling route leading to T581 phosphorylation

How can I simultaneously assess multiple phosphorylation sites on RPS6KA5 to gain insights into its activation mechanisms?

RPS6KA5 activity is regulated by phosphorylation at multiple sites beyond T581. Comprehensive analysis of its activation state requires evaluation of several phosphorylation events:

Key phosphorylation sites on RPS6KA5:

• T581: C-terminal kinase domain activation, required for autophosphorylation

• S376: N-terminal kinase domain activation, phosphorylated by ERK1/2

• T700: Stabilizes active conformation, phosphorylated by ERK1/2

• S212: N-terminal kinase domain activation, phosphorylated by p38 MAPK

Methodological approaches for multi-site analysis:

• Sequential immunoblotting:

  • Run multiple gels with identical samples

  • Probe each membrane with a different phospho-specific antibody

  • Strip and reprobe for total RPS6KA5

  • Calculate phosphorylation ratios for each site

• Phospho-proteomics analysis:

  • Immunoprecipitate RPS6KA5 from cell lysates

  • Perform tryptic digestion and LC-MS/MS analysis

  • Identify and quantify phosphopeptides corresponding to each site

  • Calculate site occupancy ratios

• Proximity ligation assay (PLA):

  • Use pairs of antibodies (e.g., anti-phospho-T581 and anti-total RPS6KA5)

  • Perform PLA to visualize and quantify specific phosphorylation events

  • Compare signals across different phosphorylation sites

• Phospho-flow cytometry:

  • Fix and permeabilize cells

  • Stain with fluorophore-conjugated phospho-specific antibodies

  • Analyze by flow cytometry to quantify phosphorylation at single-cell level

Understanding the phosphorylation pattern across multiple sites provides deeper insights into the activation mechanisms and potential cross-talk between different signaling pathways converging on RPS6KA5.

What methodological approaches can address conflicting data when studying T581 phosphorylation under different experimental conditions?

Researchers occasionally encounter conflicting data when studying T581 phosphorylation, particularly across different cell types or experimental conditions. Systematic troubleshooting and method optimization can help resolve these discrepancies:

• Standardization of stimulation protocols:

  • Define precise stimulus concentrations and durations

  • Ensure consistent cell density and growth conditions

  • Control for cell cycle stage effects on phosphorylation

  • Document detailed protocols for reproducibility

• Comprehensive pathway analysis:

  • Use specific inhibitors to dissect contributing pathways

  • Consider potential cross-talk between pathways (e.g., p38 MAPK and ERK)

  • Measure activity of upstream kinases in parallel

  • Evaluate the contribution of phosphatases (e.g., PP1, PP2A)

• Technical validation across methods:

  • Compare results from multiple detection techniques:

    • Western blotting

    • Immunofluorescence

    • ELISA

    • Mass spectrometry

  • Validate with different antibody clones or sources

• Cell type-specific considerations:

  • Account for differential expression of scaffold proteins

  • Evaluate expression levels of relevant phosphatases

  • Consider compartmentalization of signaling components

  • Document cell passage number and culture conditions

• Data integration strategies:

  • Perform time-course experiments with fine temporal resolution

  • Use mathematical modeling to integrate conflicting datasets

  • Develop quantitative frameworks that accommodate cell type-specific parameters

  • Collaborate across laboratories to validate findings independently

How can Phospho-RPS6KA5 (T581) antibodies be utilized in cancer research?

RPS6KA5 phosphorylation status has emerging significance in cancer biology, particularly in relation to proliferation, apoptosis resistance, and treatment response. Phospho-RPS6KA5 (T581) antibodies can be valuable tools in cancer research through several applications:

• Biomarker development:

  • Measure T581 phosphorylation levels in patient-derived samples

  • Correlate with treatment response and clinical outcomes

  • Develop immunohistochemical scoring systems for diagnostic applications

• Drug discovery and validation:

  • Screen compounds for effects on RPS6KA5 phosphorylation

  • Evaluate on-target effects of MEK/ERK pathway inhibitors

  • Monitor adaptive responses to targeted therapies

• Resistance mechanism investigation:

  • Compare T581 phosphorylation in sensitive versus resistant cells

  • Identify alternative pathways leading to RPS6KA5 activation

  • Develop combination therapies targeting bypass mechanisms

• Functional studies:

  • Correlate T581 phosphorylation with expression of downstream genes

  • Investigate effects on chromatin remodeling and epigenetic modifications

  • Study interactions with tumor suppressor or oncogenic pathways

Given the involvement of RPS6KA5 in inflammatory gene regulation , its role in inflammation-associated cancers represents a particularly promising research direction.

What are the methodological considerations for using Phospho-RPS6KA5 (T581) antibodies in neurological research?

RPS6KA5 plays significant roles in neuronal function, with particular relevance to learning, memory, and neurodegeneration. When employing phospho-specific antibodies in neurological research, several methodological considerations become important:

• Brain region-specific analysis:

  • Different brain regions show variable baseline levels of T581 phosphorylation

  • Compare experimental conditions to region-matched controls

  • Document precise anatomical locations in published results

• Cell type-specific considerations:

  • Employ double-labeling with neuronal, astrocytic, or microglial markers

  • Use fluorescence-activated nuclear sorting (FANS) for cell type-specific analysis

  • Consider single-cell approaches to address cellular heterogeneity

• Experimental design for in vivo studies:

  • Account for circadian variations in signaling pathway activity

  • Consider effects of anesthesia on phosphorylation status

  • Establish appropriate time points for tissue collection after stimulation

• Sample preparation optimization:

  • Use rapid tissue fixation to preserve phosphorylation status

  • Include phosphatase inhibitors at all preparation steps

  • Consider phosphorylation stability during tissue processing

• Model system selection:

  • Primary neuronal cultures vs. brain slices vs. in vivo models

  • Species-specific differences in RPS6KA5 regulation

  • Age-dependent changes in signaling pathways

Given RPS6KA5's roles in histone H3 phosphorylation and immediate early gene induction , these antibodies can be particularly valuable for studying activity-dependent gene expression in neurons.

What are common causes of false positive or false negative results when using Phospho-RPS6KA5 (T581) antibodies?

Phospho-specific antibodies present unique challenges that can lead to misleading results. Understanding common pitfalls helps researchers implement appropriate controls and validation strategies:

Causes of false positive results:

• Cross-reactivity with related phosphorylation sites:

  • Similar phosphorylation motifs in related kinases

  • Phospho-threonine recognition without sequence context

• Non-specific binding due to:

  • Insufficient blocking

  • Excessive antibody concentration

  • Inappropriate secondary antibody selection

• Inadequate dephosphorylation controls:

  • Endogenous phosphatase activity during sample preparation

  • Incomplete phosphatase inhibition

• Detection system artifacts:

  • Excessive substrate development time in IHC/ELISA

  • Non-specific binding of detection reagents

Causes of false negative results:

• Rapid dephosphorylation during sample preparation:

  • Insufficient phosphatase inhibitor cocktail

  • Delayed sample processing

  • Temperature-dependent phosphatase activation

• Epitope masking:

  • Protein-protein interactions blocking antibody access

  • Conformation changes affecting epitope accessibility

  • Inadequate antigen retrieval in fixed tissues

• Suboptimal experimental conditions:

  • Incorrect antibody dilution

  • Incompatible buffer systems

  • Inappropriate incubation temperature or duration

• Signal detection limitations:

  • Low levels of target phosphorylation

  • High background obscuring specific signal

  • Inadequate sensitivity of detection system

Recommended quality control measures:

• Include positive controls (e.g., PMA-stimulated cells)

• Perform phosphatase treatment controls

• Validate with knockout/knockdown systems

• Confirm with alternative detection methods

• Use blocking peptide competition assays

How can I optimize fixation and sample preparation to preserve phosphorylation at the T581 site?

Phosphorylation states are notoriously labile during sample preparation. Optimizing preservation of the T581 phosphorylation site requires attention to several critical factors:

For cell and tissue lysates (Western blotting, ELISA):

• Rapid harvest protocol:

  • Minimize time between stimulus cessation and cell lysis

  • Process samples on ice to reduce phosphatase activity

  • Consider direct lysis in hot SDS sample buffer for immediate denaturation

• Phosphatase inhibitor cocktail composition:

  • Include sodium orthovanadate (1-2 mM) for tyrosine phosphatases

  • Add sodium fluoride (5-10 mM) for serine/threonine phosphatases

  • Include β-glycerophosphate (10 mM) for acid phosphatases

  • Consider okadaic acid (1 μM) for PP1/PP2A inhibition

• Buffer optimization:

  • Maintain pH between 7.2-7.4 to minimize acid/base-catalyzed dephosphorylation

  • Include EDTA (1-5 mM) to chelate divalent cations required for phosphatase activity

  • Use non-ionic detergents (NP-40, Triton X-100) at appropriate concentrations

For immunohistochemistry and immunofluorescence:

• Fixation optimization:

  • Paraformaldehyde (4%) for 10-15 minutes (not longer)

  • Consider dual fixation with methanol post-PFA for certain applications

  • Avoid acidic fixatives which can promote dephosphorylation

• Rapid tissue processing:

  • Minimize time between tissue collection and fixation

  • Consider perfusion fixation for animal tissues when possible

  • Use phosphatase inhibitors in all buffers during processing

• Antigen retrieval methods:

  • Compare heat-induced epitope retrieval methods:

    • Citrate buffer (pH 6.0)

    • Tris-EDTA (pH 9.0)

    • Commercial retrieval solutions

  • Optimize time and temperature for each application

  • Include phosphatase inhibitors in retrieval solutions

• Storage considerations:

  • Process fixed samples within 24-48 hours when possible

  • For longer storage, keep sections at -20°C or -80°C

  • Avoid repeated freeze-thaw cycles

These optimized protocols help ensure that observed changes in T581 phosphorylation accurately reflect biological conditions rather than technical artifacts.